IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
IPO Detail
IPO Information
Financial
Financial Report
Peer Comparison
Peer Comparison Report
Performance
Performance Report
Concord Biotech IPO is a Book Building listing on BSE,NSE exchange, with an ipo size of ₹ 1551.00 Cr. The company is based in Ahmedabad and caters to Pharmaceutical sector. Citigroup Global Markets India , Jefferies India , Kotak Mahindra Capital Company are the merchant bankers of Concord Biotech IPO. It is a MainBoard IPO which filed its Draft Red Herring Prospectus (DRHP) on 12th August 2022.
Concord Biotech IPO posted revenues of ₹ 888.48 crores and PAT of ₹ 240.08 crores in FY25 on annualised basis.
Revenue:
₹ 853.16 Cr.
EBITDA Margin:
40.47
% 
Net Worth: ₹ 1290.00 Cr.
Market Capitalisation:
₹ 7752.06 Cr.
P/E:
[●]
P/BV: 2.73 times
EV/EBITDA: 22.53 times
Financial results of Concord Biotech IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | FY23 | FY22 | FY21 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 1513.98 | 1312.79 | 1182.54 | ||
| Net Worth | 1290.00 | 1103.22 | 999.37 | ||
| Total Debt | 31.23 | 60.58 | 86.34 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
853.16 | 712.93 | 616.94 | ||
EBITDA
EBITDA on annualised basis |
345.24 | 269.63 | 327.10 | ||
PAT
PAT on annualised basis |
240.08 | 174.92 | 234.88 | ||
Concord Biotech IPO PAT Margin is 28.14 % , ROCE (Return on Capital Employed) is 24.27 % as per latest financial. The below table shows Concord Biotech IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | FY23 | FY22 | FY21 |
|---|---|---|---|
| EBITDA Margin (%) | 40.47 | 37.82 | 53.02 |
| PAT Margin (%) | 28.14 | 24.54 | 38.07 |
| EPS (₹) | 22.95 | 16.72 | 22.45 |
| ROE (%) | 18.61 | 15.86 | 23.50 |
| ROCE (%) | 24.27 | 20.55 | 28.54 |
| ROA (%) | 15.86 | 13.32 | 19.86 |
| Debt to Equity | 0.02 | 0.05 | 0.09 |
The market Capitalisation of Concord Biotech IPO is ₹ 7752.06 crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Concord Biotech IPO prospectus highlights an Return on Equity (ROE) of 18.61 % , Return on Assets (ROA) of 15.86 %, and an EBITDA Margin of 40.47 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Concord Biotech IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Concord Biotech IPO is ₹ 7752.06 Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Concord Biotech IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Concord Biotech IPO reported revenue of ₹ 888.48 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Concord Biotech IPO provide insights into sales growth, market demand, and business scalability.
Concord Biotech recorded an EBITDA of ₹ 345.24 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Concord Biotech Profit After Tax (PAT) is ₹ 240.08 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 853.16 Cr.
EBITDA Margin:
40.47
%
Net Worth: ₹ 1290.00 Cr.
Market Capitalisation:
₹ 7752.06 Cr.
P/E:
[●]
P/BV: 2.73 times
EV/EBITDA: 22.53 times
Concord Biotech operates in Pharmaceutical and Biopharma Company Having Many Niche Products. The Issue is listed on BSE,NSE in Aug, 2023. Concord Biotech IPO size was 1551.00 with Issue price of 741.00 .
Merchant Banker(s) of Concord Biotech IPO: Citigroup Global Markets India Private Limited , Jefferies India Private Limited , Kotak Mahindra Capital Company Limited
Concord Biotech IPO subscription was 24.87 X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Concord Biotech IPO listed at a listing price of 941.85 against the offer price of 741.00.
The current market price of Concord Biotech is 1798.60.
Why Us?
